BioWorld

Oct. 11, 2010

Reading the Tea Leaves for Interferon's Future in HCV

Last week's complete response letter for Human Genome Sciences Inc. and Novartis AG's Zalbin (albinterferon alfa-2b) came as no surprise given the hepatitis C drug's history. Read More

Money Raised Year to Date

More Pharma-Dumped Assets Coming Back Home to Biotech

When the Going Gets Tough, the Tough Reverse Stock Split

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

Phase I Clinical Trials Update: September 2010

FDA Approvals in September

Phase II Clinical Trials Update: September 2010

Phase III Clinical Trials Update: September 2010

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Non-U.S. Clinical Trials & Regulatory Actions: Sept. 2010

FDA Submissions, Approvals & Other Actions: Sept. 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...